dc.contributor.author | Akova, M. | |
dc.date.accessioned | 2019-12-10T11:20:40Z | |
dc.date.available | 2019-12-10T11:20:40Z | |
dc.date.issued | 2008 | |
dc.identifier.issn | 1198-743X | |
dc.identifier.uri | https://doi.org/10.1111/j.1469-0691.2007.01847.x | |
dc.identifier.uri | http://hdl.handle.net/11655/15364 | |
dc.description.abstract | Sulbactam irreversibly inhibits the hydrolytic activity of beta-lactamases. This compound is commercially available in combination with either ampicillin or cefoperazone. In each instance, the activity of the partner antibiotic against P-lactamase-producing bacteria is restored. One of the particular advantages of using sulbactam-containing combinations is that sulbactam itself has inherent activity against some Acinetobacter baumannii. Sulbactam combinations have not demonstrated strong selective pressures for extended-spectrum beta-lactamase-producing Enterobacteriaceae and vancomycin-resistant enterococci. In contrast to clavulanate, sulbactam does not induce class I (Ampc) chromosomal beta-lactamases in Enterobacteriaceae. | |
dc.language.iso | en | |
dc.publisher | Blackwell Publishing | |
dc.relation.isversionof | 10.1111/j.1469-0691.2007.01847.x | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.subject | Infectious Diseases | |
dc.subject | Microbiology | |
dc.title | Sulbactam-Containing Beta-Lactamase Inhibitor Combinations | |
dc.type | info:eu-repo/semantics/article | |
dc.type | info:eu-repo/semantics/publishedVersion | |
dc.relation.journal | Clinical Microbiology And Infection | |
dc.contributor.department | İç Hastalıkları | |
dc.identifier.volume | 14 | |
dc.identifier.startpage | 185 | |
dc.identifier.endpage | 188 | |
dc.description.index | WoS | |
dc.description.index | Scopus | |